Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12th Congress of t

Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12thCongress of the Cell Transplant Society (CTS) in Milan, Italy

NEW YORK--(BUSINESS WIRE)-- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, will be presenting several scientific presentations at the upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy July 7-11, 2013.

World-renowned scientists, along with keen young investigators, will meet to share the latest discoveries in the field of cell and stem cell transplantation as well as regenerative medicine. For more information on the conference: http://www.cts2013.org.


The titles of the abstracts being presented at this meeting are the following:

  • Development of an economical, consistent and scalable method of young porcine islet isolation and tissue culture.
  • Prolonged euglycemia following intraperitoneal transplantation of encapsulated porcine islets.
  • Characterization of young porcine tissue during maturation in tissue culture using flow cytometry.
  • Tissue energetics as a predictor of the effectiveness of piglet pancreas organ preservation.
  • Exocrine Acinar Zymogen Granule Density is an Important Determinant of Success in Young Pig Islet Isolation and Survival.

"We are honored to present these presentations at such a prestigious conference as we continue to make significant progress toward our goal of commercializing our therapies to benefit the growing worldwide diabetic community," said Dr. Lakey, Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences. "The presentation of these abstracts is another validator of our approach to tackling this worldwide disease and are pleased to be recognized by the Cell Transplant Society as we take our promising technology to the next level."

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti-inflammatory compounds. For more information: www.isletsciences.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.



Islet Sciences
Investors:
ProActive Capital Group
Jeff Ramson, 347-394-2881
jramson@proactivecapital.com

KEYWORDS:   United States  Europe  North America  New York  Italy

INDUSTRY KEYWORDS:

The article Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.